Get App

Co-Partners

Associate Partners

Last Updated : May 15, 2019 05:42 PM IST | Source: PTI

Lupin gets 3 observations from USFDA for Aurangabad plant

The USFDA carried out the inspection at the plant from May 6 to May 15.

Drug maker Lupin on May 15 said it has received three observations from the US health regulator for its Aurangabad-based manufacturing facility.

The US Food and Drug Administration (USFDA) carried out the inspection at the plant from May 6 to May 15, Lupin said in a statement.

"The inspection at the Aurangabad facility closed with three observations. The company is confident of addressing them satisfactorily," it added.

Shares of Lupin on May 15 ended 3.22 percent lower at Rs 783.10 apiece on the BSE.
First Published on May 15, 2019 05:33 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant